Factors Contributing to Increased Vascular Fibrinolytic Activity in Mongrel Dogs
Mongrel dogs have been widely used as animal models for thrombosis research (for reviews, see References [23] [24] [25] [26] [27] [28] [29] [30] . However, the use of these animals as models for chronic pulmonary arterial thrombosis has been difficult because of the rapid lysis of thrombi in their pulmonary vasculature. [31] [32] [33] In fact, the remarkable efficiency of the canine fibrinolytic system has been observed by a variety of laboratories over the past 30 years. For example, Wessler et a134 studied the fate of serum-induced thrombi released into the canine vasculature and observed the complete degradation of thrombi in the canine pulmonary arterial tree within 6 weeks. Moreover, angiographic studies by Dalen et a135 indicated that a single experimentally induced embolus remained for only 5 days in the canine pulmonary vasculature. In comparison, resolution of massive pulmonary emboli in humans is usually incomplete after 1 year. 36 Data are currently lacking on the PAs that account for the ability of the canine species to rapidly degrade fibrin clots. Therefore, experiments were designed to address this issue and define the mechanisms that account for the rapid dissolution of pulmonary emboli in mongrel dogs. In this study, we provide evidence that u-PA is the major vascular PA in mongrel dogs and that its association with platelets and its production and secretion by pulmonary arterial endothelial cells account for the increased fibrinolytic activity of the canine pulmonary vasculature.
Methods

Fibrinolytic Reagents
Human t-PA was obtained from American Diagnostica Inc. (Greenwich, Conn.). A comparison of its activity against the t-PA International Standard (National Institute for Biological Standards and Controls [NIBSC] , London, UK, Ref No. 83/517) revealed that this preparation exhibited a specific activity of 500,000 IU/mg. Commercially available urokinase ("Winkinase," Sterling-Winthrop, Rensselaer, N.Y.) was purified further by affinity chromatography on columns of p-aminobenzamidine-Sepharose and its activity compared with World Health Organization reference 66/46, NIBSC. Human PAl-1 was purified from media conditioned by a transformed human lung fibroblast cell line (SV40 W138 VA13 2RA) according to procedures described previously.37 Human fibrinogen was purchased from American Diagnostica Inc. Human and bovine a-thrombin and canine fibrinogen were purchased from Sigma Chemical Co. (St. Louis, Mo.). Canine and human plasminogen were prepared by affinity chromatography on lysine-Sepharose. 38 Antisera to human u-PA and t-PA were raised in New Zealand White rabbits according to procedures described previously.39 Antiserum to human urokinase was also purchased from American Diagnostica Inc. (product No. 389, protein-A-Sepharose-purified polyclonal antibody). Antiserum to human PAI-1 was prepared as described.39 Rabbit For activation of latent PAT-i, samples were incubated in 0.1% sodium dodecyl sulfate (SDS) (1 hour, 37°C) followed by neutralization with a 50-fold excess of Triton X-100.
SDS Gel Electrophoresis
For SDS-polyacrylamide gel electrophoresis (SDS-PAGE), SDS-polyacrylamide slab gels and buffers were prepared as described by Laemmli.45 Samples were applied to gels composed of 10-cm resolving gels of 9% acrylamide and 2-cm stacking gels of 4% acrylamide and then subjected to electrophoresis at room temperature for 16 hours or until the dye reached the bottom of the gel. Gels were analyzed by fibrin autography or reverse fibrin autography.
Direct and Reverse Fibrin Autography
Fibrin autography was performed as previously described. 39 Briefly, fibrin-agar indicator films were prepared containing 1% agarose, fibrinogen (2.4 mg/mL), human plasminogen (25 ,ug/mL), and a-thrombin (0.5 IU/mL) (all final concentrations). The solution was mixed and poured onto prewarmed glass plates. After solidification of the fibrin-agar film, the SDS gel, which had been soaked for 1.5 hours in 2.5% Triton X-100, was layered onto the film and incubated in a humid chamber. Plates were read several times within the following hours of incubation at 37°C. Lysis was complete after 6-8 hours. Plasminogen-free plates were prepared as described by Lassen46 and Schumacher and Schill.47 In brief, fibrin-agar plates were heated for 60 minutes at 80°C in a humid chamber.
For reverse fibrin autography, fibrin-agar indicator films were prepared as described above. Indicator films also contained 0.05 IU/mL urokinase, which converts plasminogen to plasmin, thus hydrolyzing the fibrin. Development of opaque, lysis-resistant zones in the otherwise clear indicator film reveals PAI activity. The gel and indicator were incubated in a moist chamber for 2 hours at 37°C and then photographed in indirect light.
Immunoprecipitation Procedures
Protein A-Sepharose CL-4B (Pharmacia) was rehydrated in 0.14 mol/L NaCl, 10 mmol/L sodium phosphate buffer containing 0.1% bovine serum albumin, 0.05% Tween 20, and 0.02% sodium azide (immunoprecipitation buffer, pH 7.4). Washed beads (100 tL, representing 8 ,ug of coupled Sepharose beads) were incubated with rabbit antiserum (40 uL) against human and bovine PAT-i, t-PA, u-PA, a2-antiplasmin, plasminogen, and nonimmune rabbit serum (40 ,uL) 
Measurement of Plasmin-Induced Clot Lysis
The in vitro lysis of canine and human clots was performed according to the procedure described by Sakata et al. 50 In brief, 3.7 mL of bovine fibrinogen (10 mg/mL, lot 90X038, Calbiochem, La Jolla, Calif.) were mixed with 120 ,ug of radiolabeled fibrinogen. Of this solution (final concentration, 1.6x 107 cpm/mL), 265 gL was mixed with 100 gIL of plasminogen (2 mg/mL) and 10 ,L of either canine or human PPP (<500 platelets/ mL). Increasing concentrations of autologous washed platelets (106/mL to 5 x 107/mL, all final concentrations) were added. Final volume was adjusted to 1 mL by addition of 0.1 mol/L Tris-HCl, pH 8.1, containing Tween 80 (final concentration, 0.01%) and bovine serum albumin (final concentration, 1 mg/mL). The mixture was clotted with a-thrombin (final concentration, 0.05 IU/mL) and CaCl2 (final concentration, 2.5 mmol/ L). The mixture was allowed to clot for 1 hour at 37°C, and the clot was freed from the wall of the tube by rimming with a toothpick. To measure fibrinolysis, 10 ,L of serum was removed from around the clot at intervals for counting the soluble radioactivity. Results were expressed as percent release of total radioactivity. In a second series of experiments, 10 ,L of platelets (109/mL) was layered on the outside of clots aged for 1 hour containing autologous PPP. To reduce platelet aggregation and allow the exogenously added platelets to interact with the surfaces of the preformed clots, hirudin (1 unit/mL final concentration; Sigma) was first incubated (10 minutes, 37°C) with the 1-hour-old rimmed clots to neutralize residual solution-phase thrombin, and then the autologous platelets were added to the tubes. Controls were processed similarly but did not contain any exogenously added platelets.
Statistical Analysis
The general selection of material and population sampling was based on standard procedures. PA activity in acidified canine PPP was measured by means of a standard plasminogen-based amidolytic assay and found to be significantly higher than the levels detected in human PPP (2.5+0.9 IU/mL versus 0.5 ±0.03 IU/mL, p =0.002; Figure 1A) . In nonacidified samples, PA activity was not detected in the chromogenic assay in canine or in human PPP (data not shown). To identify the relative molecular masses (Mr) (molecular weight) of the PAs present in canine blood, the samples were subjected to SDS-PAGE and the fibrinolytic enzymes localized by fibrin autography. Analysis of canine PPP, WBS, or platelets ( Figure 2A, lanes 1-3, respectively) revealed a M, 45 -kd lytic zone that was not present in corresponding human blood fractions ( Figure  2A, lanes 4-6, respectively) . The presence and size of the lytic zone were independent of whether human or canine plasminogen was used as substrate in the indicator gels (data not shown). A second prominent lytic zone (i.e., M, 90-110 kd) was present in both canine and human blood samples (Figure 2A, lanes 1-3 and 4-6 , respectively). Analysis of canine samples on plasminogen-depleted fibrin agar indicator plates revealed that the enzymatic activity responsible for the 45 -kd lytic zone was dependent on the presence of plasminogen in the fibrin-agar overlay in comparison to the enzymatic activity responsible for the 90-110-kd lytic zone, which did not appear to require the presence of plasminogen in the fibrin-agar overlay ( Figure 2B , compare lanes 1 and 1').
To further characterize the different lytic zones in canine PPP, immunoprecipitation experiments were performed with antisera to human PAs (i.e., t-PA, urokinase), as well as antisera to human plasminogen. Immunoprecipitates were fractionated by SDS-PAGE and the lytic zones revealed by fibrin autography. The Mr 90-110-kd lytic zone was found to result from the activity of plasmin/plasminogen ( Figure 2C, lane 2) and the activity of t-PA inhibitor complexes ( Figure  2C , lane 3) by immunoprecipitation with the respective antisera. Analysis of the plasminogen-immunodepleted samples on plasminogen-free fibrin-agar plates did not reveal a 90-110-kd lytic zone (data not shown), ruling out the possibility that a nonspecific protease was present at this molecular weight. Lytic zones were not observed in the lanes containing immunoprecipitates obtained by use of either commercial antisera to human u-PA ( Figure 2C, lane 4) or an antiserum to u-PA prepared in our laboratory (data not shown). Because the antibodies generated to human u-PA may react with only a weak avidity to the canine molecule, we used amiloride (i.e., a specific enzymatic inhibitor of human u-PA52) to investigate the presence of u-PA in canine PPP. Figure 2D indicates that the enzymatic activity responsible for the 90-110-kd lytic zone (lane 1) was unaffected by the presence of amiloride in the indicator gel. Analysis of 0.05 units of human urokinase resulted in complete inhibition of the activity of this PA on the indicator plate containing amiloride (compare lanes 2 and 2'), whereas no inhibition occurred when t-PA (0.05 IU) was studied (compare lanes 3 and 3'). (panelA, 5 pLIlane) and lysed canine platelets (panelB,10/ilane) were incubated with Sepharose-protein A beads that had been preincubated with rabbit antisera to either human plasminogen activator inhibitor-i (PAl-i) (lanes 2 and 6), a2-antiplasmin (lanes 3 and 7), and nonimmune IgG (lanes 4 and 8) . The beads were extracted with sample buffer and fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PA GE) followed by reverse fibrin autography. Lanes 1 and 5 contain the starting material before immunoprecipitation (ie., WBS and platelet lysates). Lane 9 contains 100 ng ofpurified human PA-IM.
Identification and Characterization of Canine PAIs
To complement the experiments on the PAs present in canine blood, we also analyzed the samples for PAI activity. Another indication of the high PA activity in canine PPP was the low PAI activity in the canine species compared with human PPP (6.1±2.6 versus 10.5±4.2 U/mL, p=0.001; Figure 1B) . In canine WBS, PAI activity levels were comparable to the levels found in human WBS (22.5±3.3 versus 19.1±4.6 U/mL, p=0.1; Figure 1B ). To identify canine PAls, reverse fibrin autography was used to localize the molecular weights of the fibrinolytic inhibitors after electrophoresis. A prominent 80-kd lysis-resistant zone was consistently found in canine WBS and was identified as a2-antiplasmin by immunoprecipitation (Figure 3, panel   A) . Interestingly, a 50-kd lysis-resistant zone was detected in the pellet after immunoprecipitation with antisera to PAI-1 that could not be seen in the nonimmunoprecipitated WBS ( Figure 3A) . Canine platelets displayed a 50-kd lysis-resistant zone comigrating with human PAI-1 that was immunoprecipitated with antiserum to PAI-1 ( Figure 3B ). Balance Between PA and PAI Activities of Canine Platelets
The above data obtained from direct fibrin autography and reverse fibrin autography indicate that both PA and PAI activities were associated with canine platelets. A number of possibilities could account for this observation. For example, canine platelet PAI-1 could be stored solely in a nonactive (latent) form, or canine u-PA could be associated with platelets as a proenzyme. To clarify this issue, canine platelet lysates were incubated in the presence and absence of an active PA (i.e., human t-PA), and the formation of a high-molecularweight zone that would result from the formation of complexes was analyzed. SDS-PAGE/fibrin autography analysis of platelet lysates incubated with human t-PA revealed a 110-kd zone of lysis ( Figure 4A, lane 3) that was not present in lysates incubated in the absence of t-PA ( Figure 4A, lane 2) . We complemented the experiments by using platelets washed by gel filtration, a procedure known to remove plasma proteins that are weakly associated with platelets.4' Figure 4A indicates that the 45-kd zone was present in both washed (lane 2) and gel-filtered (lane 4) canine platelets, suggesting that the enzyme responsible for this lytic zone was tightly associated with the platelets, whereas the 90-kd plasminogen-related lytic zone was not present in the platelets that were washed by gel filtration (compare lanes 2 and 4). Furthermore, incubation of t-PA with lysates obtained from gel-filtered canine platelets also resulted in the appearance of a 110-kd zone of lysis ( Figure 4A , lane 5). Because these data suggested that a PAI was present in an active form in the platelet lysates, we decided to immunologically quantify the ability of PAI-1 in canine platelets to form complexes with t-PA. Figure 4B indicates that canine platelet lysates express PAIT-activity (1.7+0.23 U/108 platelets) that is quantitatively comparable to the PAIT-activity present in lysates of human platelets (1.76±0.36 lU/108 platelets). Moreover, the PAIT-activity detected after denaturant treatment of the canine platelet lysates (3.49+1.63 IU/108 platelets) was comparable to the PAIT-activity after denaturant treatment of human platelet lysates (3.8±0.55 U/108 platelets).
Because the net PA activity is a combination of the individual PA and PAI activities that are present in a particular sample, we extended our analysis of canine platelets by experiments designed to measure net plateletassociated fibrinolytic activity by use of a standard`251-fibrin plate. Figure 4C shows the time-dependent fibrinolytic activity of canine platelet lysates on '25I-fibrin plates in the presence of purified plasminogen. In the presence of 1 mmol/L amiloride, lytic activity was suppressed significantly ( Figure 4C ). In comparison, human platelets did not induce any measurable fibrinolysis either in the presence or in the absence of amiloride during the 4-hour incubation period ( Figure 4C ).
Contribution of Canine Platelets to Fibrinolysis
To clarify the effect of canine platelets on clot lysis, we used a standard in vitro clot lysis assay system.50 Fibrin clots supplemented with PPP from canine and human subjects were prepared with autologous platelets at concentrations ranging between 106/mL and 5 x 7/mL, and the release of radioactivity in the supernatant was monitored as an indicator of clot lysis. Clots prepared with canine blood fractions were observed to lyse significantly faster than the respective clots prepared with human blood fractions (p< 10-6; Figure 5 , panel A versus panel B). Platelet-rich clots (i.e., clots prepared in the presence of >107 platelets/mL) lysed significantly (p< 10-"`) more slowly than platelet-poor clots regardless of the species. However, clots prepared in the presence of canine PPP and 106 platelets/mL lysed significantly faster than clots prepared only in the presence of canine PPP (p=0.003). In contrast, clots prepared in the presence of human PPP and 106 platelets/mL did not lyse significantly faster than the control clots prepared only in the presence of human PPP (p=0.53, Figure SB) . Because platelets are known to actively interact with fibrin deposits during their transit through the circulation, a relevant question concerned the ability of platelets to bind and subsequently influence the lysis of preformed fibrin clots. Therefore, we performed additional experiments layering platelets on the outside of clots aged for 1 hour. Canine platelets significantly enhanced clot lysis under these conditions (p=0.0002; Figure 6, panel A) . For comparison, clot lysis was delayed when human platelets were layered on clots prepared with autologous PPP (p=O.OOO1; Figure 6 , panel B).
Contribution of Canine Endothelial Cells to Fibrinolysis
Because experimentally induced thrombi in the canine pulmonary arterial system are resolved considerably faster than thrombi in other canine blood vessels,32 we decided to investigate whether pulmonary vascular endothelial cells contribute to this process. Three distinct blood vessels (i.e., pulmonary artery, aorta, and carotid artery) were harvested from a series of mongrel dogs (n=4), and the endothelial cells of these vessels were isolated and cultured in vitro for 3 days. Fibrinolytic activities expressed by these cells were initially examined by analyzing both the condi- 10,00 20 44 Time (hours) Time tioned medium and cell lysates by SDS-PAGE/fibrin autography. Figure 7 shows the data obtained from a representative mongrel dog and indicates that 3-day primary pulmonary artery conditioned medium and the corresponding lysates exhibit prominent 45 53 Although canine thrombosis models are widely used, the mechanisms underlying the ability of mongrel dogs to degrade thrombi rapidly are unknown. Therefore, initial experiments by our group confirmed and characterized a high net PA activity in canine blood fractions compared with human blood fractions ( Figure  1 ). Further analysis of canine PPP, WBS, platelets, and endothelial cells identified the PA activity as related predominantly to u-PA (Figure 2 ). In light of these data, it should be noted that three groups have previously reported a canine PA in the perfusate of isolated canine tissues54-56 or cultured canine endothelial cells57 that was not further identified. Highsmith58 isolated a PA from canine venae cavae that was a single-chain peptide (Mr, 48 kd) with a pI of 5.9 and a pH optimum between 8.0 and 9.0. The sole report presented in the literature identifying the PA activity associated with canine-derived cells is from the group of Wilkinson et al,59 who used cultured canine keratinocytes to demonstrate that the only secreted and cell-associated PA activity was a 57-kd u-PA.
Although platelets are believed to play a major role in the stabilization of thrombi because of their ability to store and release PAI-1, platelet-enhanced fibrinolysis has been observed for more than 30 years in human platelets in vitro.60-65 However, the mechanisms have not been determined. Our results indicate that canine platelets, when analyzed by direct and reverse fibrin autography, reveal both PA and PAI activity, whereas human platelets exhibit primarily PAI-1 activity. Moreover, gel-filtered canine platelets induced a dose-and time-dependent lysis of a`25I-fibrin plate ( Figure 4C ), corresponding to an activity of 75 mIU of urokinase per 108 platelets, which is about 50-fold more than has been reported for isolated human platelet membranes.10 The presence of active PAI-1 within the platelet lysates was demonstrated by addition of t-PA, which resulted in the formation of high-molecular-weight complexes ( Figure  4A ). Analysis of canine PAI-1 by a functional immunoassay revealed that, like human66,67 and porcine platelets,68 canine platelets contain PAI-1 primarily in a latent conformation that can be reactivated with denaturants ( Figure 4B ). Although canine platelet PAI-1 readily reacts with exogenous t-PA, it does not bind and complex u-PA that is associated with the platelets, suggesting that canine platelet u-PA is in a single-chain form. Previous studies on u-PA in human plasma indicating that circulating u-PA is in a proform support this finding.69 In vivo, the generation of plasmin facilitates the conversion of u-PA to its active two-chain form.69 Thus, the association of u-PA with canine platelets may lead to an increase in the fibrinolytic degradation of a thrombus in vivo. It is important to note that our data clearly indicate that both canine and human plateletrich clots lyse more slowly than platelet-poor clots ( Figure 5) ; however, canine platelets appear to have the capability of enhancing clot lysis under certain conditions (e.g., at low concentrations within the clot [ Figure   5A ] or when layered on the outside of an in vitro clot [ Figure 6A] ). Further experiments are required to determine the conditions in which canine platelets have the ability to enhance and/or modulate clot dissolution in vivo and to define the role of canine plateletassociated u-PA in vascular hemostasis.
In primary cultures of canine endothelial cells, u-PA was found to be the major cell-associated and cellsecreted PA activity. Moreover, quantification of PA activity by a fibrin plate assay and by fibrin autography revealed that pulmonary artery endothelial cells display significantly more of this u-PA activity than endothelial cells harvested from two other major vessels in the dog ( Figure 7) . Therefore, our results suggest that plateletassociated u-PA, as well as the secretion of this molecule from pulmonary artery endothelial cells, may play a major role in destabilizing thrombi in the pulmonary vascular bed of mongrel dogs. Previous data by coworkers in our group32 revealed that clots in the canine pulmonary vasculature lyse at a faster rate than in the canine inferior vena cava. Investigators using mongrel dogs in model systems of thrombosis and thrombolysis have to consider these characteristic features of the canine fibrinolytic system in the interpretations of their experiments.
